16 results about "Metastatic cell" patented technology

The application discloses application of an inhibitor targeting SLC7A7 in preparation of a drug for treating lung cancer bone metastasis, and the inhibitor targeting SLC7A7 is a small molecule compound SLCi18. The application firstly verifies high expression of SLC7A7 in lung cancer bone metastasis cells and lung cancer bone metastasis clinical tissues, and silencing the expression of SLC7A7 can inhibit the development of lung cancer bone metastasis; the small molecule compound SLCi18 as the inhibitor targeting SLC7A7 can inhibit the function of SLC7A7 in transporting methionine, and inhibit lung cancer bone metastasis; and the application provides a new target and treatment strategy for lung cancer bone metastasis.

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

The present application relates to the field of image recognition, and more particularly to a method and system for predicting and analyzing adrenal metastasis based on image recognition. The method comprises the following steps: collecting patient adrenal PET-CT monitoring images at multiple time points, and performing visual detection of metastasis at each time point, and extracting metastasis bounding boxes at multiple time points; according to the metastasis bounding box, the dynamic fluctuation analysis of the surrounding tissue microenvironment and the boundary immune influence degree evaluation are carried out, and a multi-cycle immune response intensity graph is constructed; the metastasis change trend evolution of the metastasis bounding box is carried out, and the metastasis image change trend graph at different time points is obtained; according to the metastasis bounding box, the surrounding tissue texture feature difference is identified, and the potential tumor metastatic cells are extracted. The present application predicts the future change of metastasis by dynamically predicting the development trend of adrenal metastasis, and provides more intuitive metastasis change at different time points.

The invention relates to a high-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof, the cell line is named as a human lung adenocarcinoma brain metastasis cell line A549-F3, the cell line is preserved in China Center for Type Culture Collection on March 31, 2025, and the preservation number is CCTCC NO: C2025107. The A549-F3 cell line with high invasiveness and stable brain metastasis characteristics is successfully constructed through an in-vivo circulation screening method, the defects of an existing cell line in lung adenocarcinoma brain metastasis research are overcome, and a more suitable cell model is provided for deep exploration of related mechanisms.

There is provided a gastric tissue tumour model that is three-dimensional comprising from 0.8 to 1.2 w / v % alginate, from 1.7 to 2.3 w / v % gelatin and gastric decellularized extracellular matrix (dECM). The gastric tissue model is for example an esophageal cancer tumour model which advantageously replicates the tumour microenvironment for esophageal cancer and can be used to perform a three-dimensional culture of esophageal tumour cells or metastatic cells that often metastasize into the esophagus.

The present invenon relates to the use of an-BMP4 anbodies in a method for inhibing, prevenng, and treang cancer metastasis in paents. An-BMP4 anbodies have been found to inhibit and even prevent cancer metastasis in paents. These anbodies have also been found to inhibit growth of cancerous metastac cells, thereby treang cancer metastasis.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

To provide use of isorhamnetin or pharmaceutically acceptable salts thereof in preparation of drugs for treating esophageal cancer in the technical field of biological medicines.SOLUTION: It has been found that isorhamnetin significantly inhibits malignant growth of metastatic esophageal squamous carcinoma cells and in-vivo ESCC metastatic tumors by inhibiting a fatty acid de novo synthesis pathway in tumor metabolism. Therefore, isorhamnetin can be used for developing an anti-ESCC metastatic cell growth medicine targeting an abnormally active fatty acid de novo anabolic enzyme.SELECTED DRAWING: Figure 1

Disclosed herein are immune effector cells for use in adoptive cell transfer that have chemically- or genetically-inhibited PDHB (Pyruvate dehydrogenase E1 subunit beta) expression or activity. Also disclosed are methods of inhibiting or ablating PDHB expression in immune effector cells ex vivo and methods of using these cells to treat subjects with cancer. In some embodiments, the immune effector cells are further treated with a TIMS inhibitor or genetically engineered to ablate TIM3 expression. In some embodiments, the immune effector cells are further treated with a LAGS inhibitor or genetically engineered to ablate LAG3 expression. In some cases, the PDHB gene is disrupted by insertion of the gene encoding the chimeric receptor into the PDHB gene loci of the cell. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor.

The invention discloses a small-molecule inhibitor ratenshu and application thereof, and belongs to the technical field of biological pharmacy. On the basis of mostly retaining the immunosuppressive activity of triptolide, the small-molecule inhibitor ratenshu disclosed by the invention has the advantages that the toxicity is greatly reduced, the solubility is improved, and the druggability is better. Besides, the small-molecule inhibitor ratenshu is small in side effect and high in targeting performance, the small-molecule compound capable of smoothly passing through the blood-brain barrier can treat or reduce growth of non-small cell lung cancer brain metastatic cells, and the small-molecule inhibitor ratenshu has wide application prospects when being applied to preparation of drugs for treating non-small cell lung cancer brain metastatic growth.

The application discloses a traditional Chinese medicine composition for treating cancer-induced fatigue and a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. The traditional Chinese medicine composition comprises the following raw medicinal materials: radix pseudostellariae, fructus schisandrae, radix astragali, radix codonopsis, radix atractylodis macrocephalae, poria cocos, angelica sinensis, prepared rehmannia, radix bupleuri, radix cimicifugae, silkworm chrysalis, curcuma zedoary, mountain yam, fritillaria thunbergii miq., and soap plant thorns. Main effective components of the traditional Chinese medicine composition are beta-sitosterol, luteolin, taraxerol, stigmasterol, kaempferol and quercetin, which can participate in PI3K-Akt, MAPK, Ras, FoxO and other signal pathway conduction through target points such as TP53, AKT1, EGFR, STAT3, ESR1, BCL2, IL6, HSP90AA1 and TN, and then play the roles of anti-inflammation and anti-tumor in biological processes such as inflammatory reaction, tumor growth, proliferation, invasion, angiogenesis and metastasis, and cell metabolism.

The invention discloses a bionic nano-carrier capable of reversibly regulating and controlling a blood brain barrier and application of the bionic nano-carrier. The bionic nano-carrier is of a core-shell structure, a lecithin surface modified inorganic nano-material serves as a core, a cell membrane of brain metastatic cancer cells coats the surface of the core to serve as a shell, and an A2A adenosine receptor agonist is loaded in a cell membrane coating layer. The blood brain barrier crossing efficiency is further improved; wherein the lecithin surface modified inorganic nano-material is obtained by using an oleic acid modified inorganic nano-material as a matrix and carrying out surface modification through amphiphilic ligand lecithin. The bionic nano-carrier regulates and controls the blood-brain barrier permeability in a reversible mode, the problems that the brain transfer efficiency of a brain metastatic cell membrane bionic carrier through a cell bypass path is limited, potential safety hazards exist in a traditional blood-brain barrier permeability regulation and control open means and the like are solved, and a new strategy is provided for efficient brain delivery.

An example system for cancer metastasis detection and risk prediction includes a cell identification module and a risk prediction module, where the risk prediction module is configured to analyze identified cell types and assess the likelihood of metastasis. An example computer-implemented method includes receiving a sample, identifying cancer metastatic and precursor cell types using a cell identification module, predicting the risk of metastasis occurrence using a risk prediction module, and outputting the timing and location of potential metastasis.

The application belongs to the technical field of biological medicine, discloses application of bone metastasis specific secreted protein DKK3 in early diagnosis of lung cancer bone metastasis, and specifically discloses application of a substance for detecting DKK3 in preparation of a product for diagnosing or early screening of lung cancer bone metastasis. The application discloses the relationship between secreted protein DKK3 expression and lung cancer specific bone metastasis for the first time, and verifies that secreted protein DKK3 is specifically highly expressed in serum samples of lung cancer bone metastasis patients and lung cancer bone metastasis cells, which indicates that secreted protein DKK3 can be used as a new lung cancer bone metastasis diagnostic marker, and can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.